Vect-Horus and RadioMedix Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.

This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.

GBM is the most common and most aggressive malignant type of primary brain tumors and is a serious and life-threatening condition. The theranostic agent targets the Low-Density Lipoprotein Receptor (LDLR), which is highly expressed on many cancer cells, including glioblastoma. Positron Emission Tomography (PET) imaging and biodistribution studies in human glioblastoma xenograft and orthotopic models have shown a significant accumulation of the agent within the tumor.

We are pleased that our technology, VECTrans in combination with expertise of RadioMedix will serve to advance an innovative and promising approach for glioblastoma treatment. said Alexandre Tokay, CEO of Vect-Horus This co-development project is fully aligned with our strategy to expand the use of our technology in cancer indications with high unmet medical needs.” We look forward to very compelling outcomes from our co-development project, as we seek to create new technologies for the benefit of cancer patients, by giving doctors and hospitals more imaging and treatment options.” Said Dr Jamal Temsamani, Director of Drug Development of Vect-Horus.

ALSO READ:   HarborOne Bancorp, Inc. Announces 2019 First Quarter Earnings

Development of a highly sensitive and effective theranostic approach for GBM has always been among our top priorities. Our initial evaluation of VECTrans technology appears to be extremely promising. said Dr Ebrahim Delpassand, CEO of RadioMedix. Our plan is to utilize VECTrans technology to initially develop an accurate molecular diagnostic PET/CT probe to precisely map the tumor involvement in the brain. This will significantly improve precision of the surgical resection of the tumor. The treatment will then be followed by targeted alpha-emitter or beta-emitter radionuclide therapy using the same technology to eradicate any residual malignant cells at the molecular level added Dr. Delpassand.

RadioMedix has strong interests and all expertise needed to develop the VECTrans“based radio-theranostic agents for GBM, said Izabela Tworowska, PhD, CSO of RadioMedix. Targeting LDLR can improve the blood -brain barrier (BBB) permeability of the drug and selectively deliver the isotope payload to GBM cancer cells.

About Vect-Horus Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (including the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more about Vect-Horus, visit

ALSO READ:   StoneCo Ltd. to Announce Third Quarter 2018 Financial Results on November 26, 2018

About RadioMedix RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is developing radiopharmaceuticals for PET imaging and therapy (alpha and beta-labeled). RadioMedix has also established contract service facilities for academic and industrial partners including discovery center for the probe development, a small animal molecular imaging facility for pre-clinical evaluation of radiopharmaceuticals, and full cGMP and analytical suites for late stage human clinical trials, and post approval commercial manufacturing. To learn more, visit and LinkedIn.

Elodie Dormes
Business Development Manager
[email protected]

Izabela Tworowska, PhD,
[email protected]